DXR
HEALTHCAREDaxor Corp
$10.14-0.71 (-6.58%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DXR Today?
No stock-specific AI insight has been generated for DXR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.19$14.76
$10.14
Fundamentals
Market Cap$59M
P/E Ratio6.2
EPS$1.64
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin343.6%
Debt / Equity—
Trading
Volume22K
Avg Volume (10D)—
Shares Outstanding5.8M
DXR News
20 articles- Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume AnalysisYahoo Finance·Apr 28, 2026
- Dynamic announces April 2026 cash distributions for Dynamic Active ETFs and ETF SeriesYahoo Finance·Apr 20, 2026
- Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology CenterYahoo Finance·Apr 8, 2026
- Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026Yahoo Finance·Mar 26, 2026
- Dynamic announces March 2026 cash distributions for Dynamic Active ETFs and ETF SeriesYahoo Finance·Mar 19, 2026
- Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced ReadmissionsYahoo Finance·Mar 17, 2026
- Daxor Details Portable FDA-Cleared Blood Volume Analyzer, 'Razor-and-Blades' Kit Growth at iAccess AlphaMarketbeat·Mar 15, 2026
- Updated Lineup Announced for the iAccess Alpha Virtual Best Ideas Spring Investment Conference March 10-11, 2026Yahoo Finance·Mar 10, 2026
- Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care CongressYahoo Finance·Mar 10, 2026
- Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026Yahoo Finance·Mar 9, 2026
- Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to ShareholdersYahoo Finance·Mar 3, 2026
- Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per ShareYahoo Finance·Mar 3, 2026
- Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in TennesseeYahoo Finance·Feb 24, 2026
- Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic BusinessYahoo Finance·Feb 10, 2026
- Daxor Corporation Announces $9 Million Registered Direct OfferingYahoo Finance·Jan 23, 2026
- Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA AnalyzerYahoo Finance·Nov 25, 2025
- Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth SummitYahoo Finance·Oct 21, 2025
- Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25Yahoo Finance·Oct 15, 2025
- Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSAYahoo Finance·Sep 30, 2025
- Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific MeetingYahoo Finance·Sep 23, 2025
All 20 articles loaded
Price Data
Open$11.24
Previous Close$10.85
Day High$11.24
Day Low$10.00
52 Week High$14.76
52 Week Low$7.19
52-Week Range
$7.19$14.76
$10.14
Fundamentals
Market Cap$59M
P/E Ratio6.2
EPS$1.64
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin343.6%
Debt / Equity—
Trading
Volume22K
Avg Volume (10D)—
Shares Outstanding5.8M
About Daxor Corp
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.
HEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL INSTRUMENTS & SUPPLIES
CIK—
Composite FIGI—
Share Class FIGI—